Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 3;4(5):e218505.
doi: 10.1001/jamanetworkopen.2021.8505.

An Empirically Derived Definition of Metabolically Healthy Obesity Based on Risk of Cardiovascular and Total Mortality

Affiliations

An Empirically Derived Definition of Metabolically Healthy Obesity Based on Risk of Cardiovascular and Total Mortality

Anika Zembic et al. JAMA Netw Open. .

Abstract

Importance: People classified by a priori definitions as having metabolically healthy obesity have frequently been found to be at increased risk of mortality, compared with individuals with metabolically healthy normal weight, suggesting these definitions may be insufficient.

Objectives: To systematically derive a new definition of metabolic health (MH) and investigate its association with cardiovascular disease (CVD) mortality and total mortality.

Design, setting, and participants: In a cohort study using data from the third National Health and Nutrition Examination Survey (NHANES-III), a representative survey using complex multistage probability sampling, anthropometric factors, biomarkers, and blood pressure (BP) associated with total and CVD mortality among participants with obesity were identified with Cox proportional hazards regression. Area under the receiver operating characteristic was calculated to identify predictive factors for mortality to be used to define MH, cutoff levels were determined by the Youden index, and the findings were validated through comparison with the independent UK Biobank cohort, a population-based prospective study. All nonpregnant participants in the databases aged 18 to 75 years with no history of CVD, body mass index greater than or equal to 18.5, and who fasted 6 or more hours before examination in NHANES-III were included; participants in the UK Biobank cohort who did not have blood measurements were excluded. The study was conducted from 2015 to 2020.

Exposures: Body mass index and MH were defined by the new definition and compared with 3 a priori definitions.

Main outcomes and measures: Cardiovascular disease mortality and total mortality.

Results: Within the NHANES-III (n = 12 341) cohort, mean (SD) age was 41.6 (29.2) years, 50.7% were women, and mean follow-up was 14.5 (2.7) years. Within the UK Biobank (n = 374 079) cohort, mean (SD) age was 56.2 (8.1) years, 55.1% were women, and mean follow-up was 7.8 (1.0) years. Use of blood pressure (BP)-lowering medication (hazard ratio [HR] for CVD mortality, 2.41; 95% CI, 1.50-3.87 and total mortality, 2.05; 95% CI, 1.47-2.84), diabetes, and several continuous factors were associated with mortality. Of all significant continuous factors, the combination of systolic BP and waist-to-hip ratio showed the highest area under the receiver operating characteristic (CVD mortality: 0.775; 95% CI, 0.770-0.781; total mortality: 0.696; 95% CI, 0.694-0.699). Thus, MH was defined as systolic BP less than 130 mm Hg, no BP-lowering medication, waist-to-hip ratio less than 0.95 for women and less than 1.03 for men, and no self-reported (ie, prevalent) diabetes. In both cohorts, metabolically healthy obesity was not associated with CVD and total mortality compared with metabolically healthy normal weight. For NHANES-III, the hazard ratio was 0.68 (95% CI, 0.30-1.54) for CVD mortality and 1.03 (95% CI, 0.70-1.51) for total mortality. For UK Biobank, the hazard ratio was 1.17 (95% CI, 0.81-1.69) for CVD mortality and 0.98 (95% CI, 0.87-1.10) for total mortality. Regardless of body mass index, all metabolically unhealthy groups displayed increased risks.

Conclusions and relevance: This newly proposed definition of MH may identify a subgroup of people with obesity without increased risk of mortality and stratify risks in people who are overweight or normal weight.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Zembic reported grants from German Federal Ministry of Education and Research (BMBF) DZD grant 82DZD00302 during the conduct of the study. Dr Eckel reported grants from German Federal Ministry of Education and Research (BMBF) DZD grant 82DZD00302 during the conduct of the study. Dr Schulze reported grants from German Federal Ministry of Education and Research during the conduct of the study. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Weighted Prevalence and Overlap of Metabolically Healthy Obesity (MHO) Identified by Different Definitions Within the National Health and Nutrition Examination Survey-III (NHANES-III) (n = 12 341)
ATP-III indicates Adult Treatment Panel-III; HOMA-IR, homeostatic model assessment of insulin resistance.
Figure 2.
Figure 2.. Risk of Mortality in Subgroups of Body Mass Index and Metabolic Health Using a New Definition
Hazard ratios (95% CIs) adjusted for age, sex, race/ethnicity, educational level, income, marital status, smoking status, alcohol consumption, physical activity, and UK Biobank assessment center. National Health and Nutrition Examination Survey-III (NHANES-III) cohort, n = 12 341; UK Biobank cohort, n = 374 079. CVD indicates cardiovascular disease; MHNW, metabolically healthy normal weight; MHO metabolically healthy obese; MHOW, metabolically healthy overweight; MUHNW, metabolically unhealthy normal weight; MUHO, metabolically unhealthy obese; and MUHOW, metabolically unhealthy overweight.

Comment in

  • Metabolically Healthy Obesity Redefined.
    April-Sanders AK, Rodriguez CJ. April-Sanders AK, et al. JAMA Netw Open. 2021 May 3;4(5):e218860. doi: 10.1001/jamanetworkopen.2021.8860. JAMA Netw Open. 2021. PMID: 33961041 No abstract available.

References

    1. Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6(12):944-953. doi: 10.1016/S2213-8587(18)30288-2 - DOI - PMC - PubMed
    1. Stefan N, Häring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol. 2018;6(3):249-258. doi: 10.1016/S2213-8587(17)30292-9 - DOI - PubMed
    1. Schulze MB. Metabolic health in normal-weight and obese individuals. Diabetologia. 2019;62(4):558-566. doi: 10.1007/s00125-018-4787-8 - DOI - PubMed
    1. Stefan N, Häring HU, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1(2):152-162. doi: 10.1016/S2213-8587(13)70062-7 - DOI - PubMed
    1. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? a systematic review and meta-analysis. Ann Intern Med. 2013;159(11):758-769. doi: 10.7326/0003-4819-159-11-201312030-00008 - DOI - PubMed

Publication types